

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

U.S. PATENT DOCUMENTS

EXAM- INER INITIAL	REF NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AJ3	4,822,777	04-18-1989	Abra
	AK3	5,498,421	03-12-1996	Grinstaff, <i>et al.</i>
	AA4	5,560,933	10-01-1996	Soon-Shiong, <i>et al.</i>
	AB4	5,665,382	09/09/1997	Grinstaff, <i>et al.</i>
	AC4	5,739,686	04/14/1998	Naughton, <i>et al.</i>
	AD4	5,840,746	11-24-1998	Ducharne <i>et al.</i>
	AE4	5,916,596	06/29/1999	Desai, <i>et al.</i>
	AF4	6,096,331	08/01/2000	Desai, <i>et al.</i>
	AG4	6,214,863	04-10-2001	Bissery, <i>et al.</i>
	AH4	6,506,405	01/14/2003	Desai, <i>et al.</i>
	AI4	6,537,579	03/25/2003	Desai, <i>et al.</i>
	AJ4	6,749,868	06/15/2004	Desai, <i>et al.</i>
	AK4	6,753,006	06/22/2004	Desai, <i>et al.</i>
	AA5	7,250,432	07/31/2007	Kwon, <i>et al.</i>
	AB5	7,345,094	03/18/2008	Koya, <i>et al.</i>
	AC5	7,368,473	05/06/2008	Koya, <i>et al.</i>
	AD5	7,435,843	10/14/2008	Chen, <i>et al.</i>
	AE5	US 2004/0022869	02/05/2004	Chen, <i>et al.</i>
	AF5	US 2004/235813 A1	11-25-2004	Wanker, <i>et al.</i>
	AG5	US 2005/154039 A1	07-14-2005	Glacera Contour, <i>et al.</i>

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for Form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson		CONFIRMATION NO. 5403	GROUP 1614

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
	AH5	US 2006/0167106	11-27-2006	Zhang, <i>et al.</i>
	AI5	US 2006/0270873	11-30-2006	Chen, <i>et al.</i>
	AJ5	US 2007/0088057	07/19/2007	Lunsmann, <i>et al.</i>
	AK5	US 2008/0089950 A1	04-17-2008	Chen <i>et al.</i>
	AA6	US 2008/0118562	05-22-2008	Koya
	AB6	US 2008/0119440	05-22-2008	Koya
	AC6	US 2008/0146842	06-19-2008	Koya, <i>et al.</i>
	AD6	US 2008/0176828	07-24-2008	Koya, <i>et al.</i>
	AE6	US 2008/0214655 A1	09-04-2008	Koya <i>et al.</i>
	AF6	US 2008/0226588	09-18-2008	McLeod
	AG6	US 2008/0242702 A1	10-02-2008	Koya <i>et al.</i>
	AH6	US 2008/0269340 A1	10-30-2008	Koya <i>et al.</i>
	AI6	US 2009/0005594 A1	01-01-2009	Chen <i>et al.</i>
	AJ6	US 2009/0042991 A1	02-12-1999	Barsoum <i>et al.</i>
	AK6			
	AA7			
	AB7			

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001	APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya	FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES	NO
AM3	AU 2006/228035 A1	11-02-2006	Synta Pharmaceuticals Corp.		
AN2	CH 482294A	12-15-1969	Shell Int. Research		X
AQ3	DE 2037257	02-03-1973	Farbwerte Hoechst A.G.		X
AP3	EP 1 731 148 A	12-13-2006	Synta Pharmaceuticals Corp.		
AQ3	EP 1406869 B1	09-13-2006	Synta Pharmaceuticals Corp.		
AL4	EP 1454628 A	09-08-2004	Seoul National University Industry Foundation		
AM4	EP 1493445 A	01-05-2005	Max Planck Gesellschaft		
AN4	JP 07-165693	06-27-1995	Rohm & Haas Co.		X
AQ4	JP 10-501215	02-03-1998	BASE AG		X
AP4	JP 63-267752	11-04-1988	Rohm & Haas Co.		X
AQ4	WO 03/006429 A1	01-23-2003	SBR Pharmaceuticals Corp.		
AL5	WO 03/047524 A2	06-12-2003	Dana-Farber Cancer Institute		
AM5	WO 2004/072051	08-26-2004	Vernalis Cambridge Ltd.		
AN5	WO 2005/028475 A2	03-31-2005	Vertex Pharma		
AO5	WO 2005/097758 A1	10-20-2005	Amphora Discovery Corp.		
AP5	WO 2006/009940	01-26-2006	Synta Pharmaceuticals Corp.		
AQ5	WO 2006/055747 A2	05-26-2006	Synta Pharmaceuticals Corp.		
AL6	WO 2006/062732 A2	06-15-2006	Synta Pharmaceuticals Corp.		
AM6	WO 2006/089177 A2	08-24-2006	Synta Pharmaceuticals Corp.		

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 14493/PFC SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson		CONFIRMATION NO. 5403	GROUP 1614

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
	AN6	WO 2007/021881 A2	02-22-2007	Synta Pharmaceuticals Corp.		
	AO6	WO 2007/139955 A2	12-06-2007	Synta Pharmaceuticals Corp.		
	AP6	WO 2008/024298 A1	02-28-2008	Synta Pharmaceuticals Corp.		
	AQ6	WO 2008/024299	02-28-2008	Synta Pharmaceuticals Corp.		
	AL7	WO 2008/024301 A2	02-28-2008	Synta Pharmaceuticals Corp.		
	AM7	WO 2008/024302 A2	02-28-2008	Synta Pharmaceuticals Corp.		
	AN7	WO 2008/024303 A2	02-28-2008	Synta Pharmaceuticals Corp.		
	AO7	WO 2008/024305 A2	02-28-2008	Synta Pharmaceuticals Corp.		
	AP7	WO 2008/027445 A2	03-06-2008	Synta Pharmaceuticals Corp.		
	AQ7	WO 2008/033300 A2	03-20-2008	Synta Pharmaceuticals Corp.		
	AL8	WO 2008/033449 A2	03-20-2008	Synta Pharmaceuticals Corp.		
	AM8	WO 2008/033494 A2	03-20-2008	Synta Pharmaceuticals Corp.		
	AN8	WO 2008/082579 A1	07-10-2008	Synta Pharmaceuticals Corp.		
	AO8	WO 2009/020631 A2	02-12-2009	Synta Pharmaceuticals Corp.		
	AP8					
	AQ8					

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AS3	"The Merck Manual," Chapter 14: Principles of Cancer Therapy, 1999 Merck Research Laboratories, Pages 987-995 (1999), XP002477370.
	AT3	Abuchowski, A., <i>et al.</i> , "Alteration of Immunological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol," <i>The Journal of Biological Chemistry</i> 252(11):3578-3581 (1977).
	AU3	Ashburner, M. and Bonner, J.J., "The Induction of Gene Activity in <i>Drosophila</i> by Heat Shock," <i>Cell</i> 17: 241-254 (1979).
	AV3	Auluck, P.K., <i>et al.</i> , "Chaperone Suppression of α -Synuclein Toxicity in a <i>Drosophila</i> Model for Parkinson's Disease," <i>Science</i> , 295: 865-868 (2002).
	AW3	Bahceci, et al., "Reactions of amidines with some carboxylic acid hydrazides," <i>Indian Journal of Chemistry Section B</i> , vol. 44B, 2005, pp. 568-572, XP009083365, page 569, Scheme 1.
	AX3	Balkwill, F. <i>et al.</i> , "Inflammation and Cancer: Back to Virchow?" <i>The Lancet</i> , 357: 539-545 (February 2001).
	AY3	Barclay, J.W. and Roberson, R.M., "Role for Calcium in Heat Shock-Mediated Synaptic Thermoprotection in <i>Drosophila</i> Larvae," <i>J. Neurobiol.</i> , 56(4): 360-371 (2003).
	AZ3	Beck, F-X., <i>et al.</i> , "Molecular Chaperones in the Kidney: Distribution, Putative Roles, and Regulation," <i>Am. J. Physiol. Renal. Physiol.</i> , 279: F203-F215 (2000).
	AR4	Beillerot, et al., "Synthesis and protective effects of coumarin derivatives against oxidative stress induced by doxorubicin," <i>Bioorganic & Medicinal Chemistry Letters</i> , Oxford, GB, vol. 18, no. 3, 27 December 2007, pp. 1102-1105, XP022475694, ISSN: 0960-894X.
	AS4	Bellmann, K., <i>et al.</i> , "Heat Shock Induces Resistance in Rat Pancreatic Islet Cells against Nitric Oxide, Oxygen Radicals and Streptozotocin Toxicity In Vitro," <i>J. Clin. Invest.</i> , 95(6): 2840-2845 (1995).
	AT4	Berge, <i>et al.</i> , "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> , 66 (1): 1-19, 1977.
	AU4	Biagi, G. <i>et al.</i> , "1,5-Diarylsubstituted 1,2,3-triazoles as Potassium Channel Activators. VI," <i>Il Farmaco</i> , 59(5): 397-404 (2004), esp. page 398.
	AV4	Blondeau, N., <i>et al.</i> , "Polyunsaturated Fatty Acids Induce Ischemic and Epileptic Tolerance," <i>Neuroscience</i> , 109(2): 231-241 (2002).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref No	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AW4	Brittain <i>et al.</i> , in <i>Polymorphism in Pharmaceutical Solids</i> , (NY: M. Dekker), Vol. 95, pp. 348-361 (1999).
	AX4	Cancer, Wikipedia, http://en.wikipedia.org/wiki/Cancer (1 of 40) 8/2/2008 (all pages).
	AY4	Carmel, J.B., <i>et al.</i> , "Mediators of Ischemic Preconditioning Identified by Microarray Analysis of Rat Spinal Cord," <i>Exp. Neurol.</i> , 185: 81-96 (2004).
	AZ4	Carter, R. J., <i>et al.</i> , "Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington's Disease Mutation," <i>J. Neuroscience</i> , 19(8): 3248-3257 (1999).
	AR5	Chen, H-C., <i>et al.</i> , "Induction of Heat Shock Protein 70 Protects Mesangial Cells Against Oxidative Injury," <i>Kidney Int.</i> , 56: 1270-1273 (1999).
	AS5	Clathrate: Lewis, Hawley's Condensed Chemical Dictionary, 14 th Edition, 1997, Van Nostrand Reinhold.
	AT5	Craig, E. A., "The Heat Shock," <i>Crit. Rev. Biochem.</i> , 18(3): 239-280 (1985).
	AU5	Doi, Y., <i>et al.</i> , "Effect of HSP70 Induced by Warm Ischemia to the Liver on Liver Function after Partial Hepatectomy," <i>Hepato-Gastroenterology</i> , 48: 533-540 (2001).
	AV5	Dunn, S.E., <i>et al.</i> , "Polystyrene-Poly (Ethylene Glycol) (PS-PEG2000) Particles as Model Systems for Site Specific Drug Delivery. 2. The Effect of PEG Surface Density on the <i>in Vitro</i> Cell Interaction and <i>in Vivo</i> Biodistribution," <i>Pharmaceutical Research</i> 11(7):1016-1022 (1994).
	AW5	Dvorak, H.F., <i>et al.</i> , "Identification and Characterization of the Blood Vessels of Solid Tumors That Are Leaky to Circulating Macromolecules," <i>American Journal of Pathology</i> 133(1):95-109 (1988).
	AX5	Gabizon, A.A., "Selective Tumor Localization and Improved Therapeutic Index of Anthracyclines Encapsulated in Long-Circulating Liposomes," <i>Cancer Research</i> 52:891-896 (1992).
	AY5	Gao, Y., <i>et al.</i> , "Protein Kinase C-dependent Activation of P44/42 Mitogen-activated Protein Kinase and Heat Shock Protein 70 in Signal Transduction During Hepatocyte Ischemic Preconditioning," <i>World J. Gastroenterol.</i> , 10(7): 1019-1027 (2004).
	AZ5	Garlock, K., "Experimental Treatment Gives a Cancer Patient Hope," <i>The Charlotte Observer</i> [online], April 25, 2005 [retrieved on 2008-05-23]. Retrieved from the Internet URL: http://www.ericandfran.com/charlotte_observer_april_25.htm .

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AR6		Gavezzotti, "Are crystal structures predictable?," Accounts of Chemical Research, 27:309-314, 1994.
AS6		Gawande, N.G., et al., "Synthesis of some thiosemicarbazides and related compounds," CAPLUS, 1989, XP002391517.
AT6		Gehrmann, M., "Drug Evaluation: STA-4783 - Enhancing Taxane Efficacy by Induction of Hsp70," <i>Current Opinion in Investigational Drugs</i> , 7(6): 574-580 (June 2006), XP008087326.
AU6		Georgopoulos, C. and Welch, W. J., "Role of the Major Heat Shock Proteins as Molecular Chaperones," <i>Annu. Rev. Cell Biol.</i> , 9: 601-634 (1993).
AV6		Golub <i>et al.</i> , <i>Science</i> , vol. 286, 1999, pp. 531-537.
AW6		Gref, R., <i>et al.</i> , "Biodegradable Long-Circulating Polymeric Nanospheres," <i>Science</i> 263:1600-1603 (1994).
AX6		Gurney, M. E., <i>et al.</i> , "Motor Neuron Degeneration in Mice That Express a Human Cu,Zn Superoxide Dismutase Mutation," <i>Science</i> , 264: 1772-1775 (1994).
AY6		Hiratsuka, M., <i>et al.</i> , "Heat Shock Pretreatment Protects Pulmonary Isografts from Subsequent Ischemia-reperfusion Injury," <i>J. Heart Lung Transplant</i> , 17(12): 1238-1246 (1998).
AZ6		Holcomb, L., <i>et al.</i> , "Accelerated Alzheimer-Type phenotype in transgenic mice carrying both mutant <i>amyloid precursor protein</i> and <i>presenilin 1</i> transgenes," <i>Nature Medicine</i> , 4(1): 97-100 (1998).
AR7		Howland, D. S., <i>et al.</i> , "Focal Loss of the Glutamate Transporter Ea2 in a Transgenic Rat Model of Sod1 Mutant-mediated Amyotrophic Lateral Sclerosis (ALS)," <i>Proc. Nat. Acad. Sci. USA</i> , 99(3): 1604-1609 (2002).
AS7		Ichihara, et al., "Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity," Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, US, vol. 359, no. 1, 2 June 2007, pp. 27-33, XP022103137, ISSN: 0006-291X.
AT7		Inclusion complex: Lewis, Hawley's Condensed Chemical Dictionary, 14 th Edition, 1997, Van Nostrand Reinhold.
AU7		Ishii, Y., <i>et al.</i> , "Retinal Ganglion Cell Protection with Geranylgeranylacetone, a Heat Shock Protein Inducer, in a Rat Glaucoma Model," <i>Invest. Ophthalmol. Vis. Sci.</i> , 44(5): 1982-1992 (2003).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref No	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AV7	Jacquier-Sarlin, M.R. <i>et al.</i> , "Protective Effects of hsp70 in Inflammation," <i>Experientia</i> , 50(11-12): 1031-1038 (November 1994).
	AW7	Johnson, A.D., <i>et al.</i> , "Differential Distribution of 70-kD Heat Shock Protein in Atherosclerosis," <i>Arterio Thromb Vasc Biol</i> , 15(1): 27-36 (1995).
	AX7	Kandror, O. and Goldberg, A.L., "Trigger Factor is Induced Upon Cold Shock and Enhances Viability of <i>Escherichia coli</i> at Low Temperatures," <i>Proc Natl Acad Sci USA</i> , 94(10): 4978-4981 (1997).
	AY7	Kelly, S. and Yenari, M.A., "Neuroprotection: Heat Shock Proteins," <i>Curr Res Med Opin</i> , 18(Suppl. 2): s55-s60 (2002).
	AZ7	Keswani, <i>et al.</i> , "FK506 Is Neuroprotective in a Model of Antiretroviral Toxic Neuropathy," <i>Annals Neurology</i> , 53(1): 57-64 (2003).
	AR8	Kiang, J.G. and Tsokos, G.C., "Heat Shock Protein 70 kDa: Molecular Biology, Biochemistry, and Physiology," <i>Pharmacol Ther</i> , 80(2): 183-201 (1998).
	AS8	Klettner, A. and Herdegen, T., "The Immunophilin-Ligands FK506 and V-10,367 Mediate Neuroprotection by the Heat Shock Response," <i>Br J Pharmacol</i> , 138(5): 1004-1012 (2003).
	AT8	Klettner, A., "The Induction of Heat Shock Proteins as a Potential Strategy to Treat Neurodegenerative Disorders," <i>Drug News Perspect</i> , 17(5): 299-306 (2004).
	AU8	Klibanov, A., <i>et al.</i> , "Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes," <i>FEBS</i> 268(1):235-237 (1990).
	AV8	Langston, J.W., <i>et al.</i> , "Selective Nigral Toxicity After Systemic Administration of 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine (MPTP) in the Squirrel Monkey," <i>Brain Res</i> , 292: 390-394 (1984).
	AW8	Lee, J.E., <i>et al.</i> , "Differential Neuroprotection From Human Heat Shock Protein 70 Overexpression in <i>in Vitro</i> and <i>in Vivo</i> Models of Ischemia and Ischemia-Like Conditions," <i>Exp Neurol</i> , 170(1): 129-139 (2001).
	AX8	Lepore, D.A., <i>et al.</i> , "Role of Priming Stresses and Hsp70 in Protection From Ischemia-Reperfusion Injury in Cardiac and Skeletal Muscle," <i>Cell Stress & Chaperones</i> , 6(2): 93-96 (2001).
	AY8	Lindquist, S., "The Heat-Shock Response," <i>Ann Rev Biochem</i> , 55: 1151-1191 (1986).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1-449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
AZ8		Longa, E.Z., <i>et al.</i> , "Reversible Middle Cerebral Artery Occlusion Without Craniectomy in Rats," <i>Stroke</i> , 20(1): 84-91 (1989).
AR9		Malberg, J.E. and Seiden, L.S., Poster "MDMA Administration Induces Expression of HSP70 in the Rat Brain." Society for Neuroscience Annual Meeting, New Orleans, LA, October 25-30, 1997.
AS9		Mangiarini, L., <i>et al.</i> , "Exon 1 of the <i>HD</i> Gene With an Expanded CAG Repeat is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice," <i>Cell</i> , 87: 493-506 (1996).
AT9		Marber, M.S., <i>et al.</i> , "Overexpression of the Rat Iducible 70-kD Heat Shock Protein in a Transgenic Mouse Increases the Resistance of the Heart to Ischemic Injury," <i>J Clin Invest</i> , 95: 1446-1456 (1995).
AU9		Milas, <i>et al.</i> , "Chemoradiotherapy: emerging treatment improvement strategies," published online 6 December 2003 in Wiley InterScience (www.interscience.wiley.com)
AV9		Minowada, G. and Welch, W.J., "Clinical Implications of the Stress Response," <i>J Clin Invest</i> , 95: 3-12 (1995).
AW9		Morimoto, <i>et al.</i> , In: <i>The Biology of Heat Shock Proteins and Molecular Chaperone</i> . (NY: Cold Spring Harbor Laboratory Press) pp. 417-455 (1994).
AX9		Mosser, D.D., <i>et al.</i> , "The Chaperone Function of hsp70 Is Required for Protectin Induced Apoptosis," <i>Mol Cell Biol</i> , 20(19): 7146-7159 (2000).
AY9		Papahadjopoulos, D., <i>et al.</i> , "Sterically Stabilized Liposomes: Improvements in Pharmacokinetics and Antitumor Therapeutic Efficacy," <i>Proc. Natl. Acad. Sci. USA</i> 88:11460-11464 (1991).
AZ9		Patani, <i>et al.</i> , "Bioisosterism: A Rational Approach in Drug Design," <i>Chem. Rev.</i> , 96: 3147-3176 (1996), esp. page 3152.
AR10		Plumier, J.-C. L., <i>et al.</i> , "Transgenic Mice Expressing the Human Heat Shock Protein 70 Have Improved Post-Ischemic Myocardial Recovery," <i>J Clin Invest</i> , 95: 1854-1860 (1995).
AS10		Radford, N.B., <i>et al.</i> , "Cardioprotective Effects of 70-kDa Heat Shock Protein in Transgenic Mice," <i>Proc Natl Acad Sci USA</i> , 93(6): 2339-2342 (1996).
AT10		Rao <i>et al.</i> , "Combination of Paclitaxel and Carboplatin as Second-Line Therapy for Patients with Metastatic Melanoma," <i>Cancer</i> , Vol 106, No. 2: 375-382 (2006).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AU10	Renshaw, G.M.C., <i>et al.</i> , "Oxygen Sensors and Energy Sensors Act Synergistically to Achieve a Graded Alteration in Gene Expression: Consequences for Assessing the Level of Neuroprotection in Response to Stressors," <i>Front Biosci</i> , 9: 110-116 (2004).
	AV10	Sanchez, <i>et al.</i> , "New naphthylcombrestatins. Modifications on the ethylene bridge," <i>Bioorganic and Medicinal Chemistry</i> , vol. 13, no. 6, March 2005, pp. 2097-2107, XP002470852, ISSN: 0968-0896.
	AW10	Sato, K., <i>et al.</i> , "HSP70 is Essential to the Neuroprotective Effect of Heat-Shock," <i>Brain Res</i> , 740(1-2): 117-123 (1996).
	AX10	Sauer, H. and Oertel, W.H., "Progressive Degeneration of Nigrostriatal Dopamine Neurons Following Intrastratial Terminal Lesions with 6-Hydroxydopamine: A Combined Retrograde Tracing and Immunocytochemical Study in the Rat," <i>Neuroscience</i> , 59(2): 401-415 (1994).
	AY10	Savage, E., <i>et al.</i> , Living with Melanoma, [online], [retrieved on 2006-08-09]. Retrieved from the Internet URL: http://ericandfran.com/melanoma.htm .
	AZ10	Shin, K.D., <i>et al.</i> , "Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation" <i>Journal of Biological Chemistry</i> , American Society of Biochemical Biologists, Birmingham, US, vol. 280 no. 50, 18 October 2005 (2005-10-18), pp. 41439-41448, XP002391924, ISN: 0021-9258.
	AR11	Simon, M.M., <i>et al.</i> , "Heat Shock Protein 70 Overexpression Affects the Response to Ultraviolet Light in Murine Fibroblasts," <i>J Clin Res</i> , 95(3): 926-933 (1995).
	AS11	Sobue, G., "Molecular Pathogenesis of Motor Neuron Diseases (In Japanese) English abstract, <i>Nihon Shinkei Seishin Yakurigaku Zasshi</i> , 21(1): 21-25 (2001).
	AT11	Tavaria, M. <i>et al.</i> , "A Hitchhiker's Guide to the Human Hsp70 Family," <i>Cell Stress Chaperones</i> , 1(1): 23-28 (1996).
	AU11	Todryk, S.M., <i>et al.</i> "Facets of Heat Shock Protein 70 Show Immunotherapeutic Potential," <i>Immunology</i> , 110(1): 1-9 (2003).
	AV11	Tsuchiya, D., <i>et al.</i> , "Overexpression of Rat Heat Shock Protein 70 Reduces Neuronal injury After Transient Focal Ischemia, Transient Global Ischemia, or Kainic Acid-Induced Seizures," <i>Neurosurgery</i> , 53(5): 1179-1187 (2003).
	AW11	Valeriote, F., <i>et al.</i> "Synergistic Interaction of Anticancer Agents: A Cellular Perspective," <i>Cancer Chemotherapy Reports</i> , 59(5): 895-900 (1975).

EXAMINER	DATE CONSIDERED
----------	-----------------

Substitute for form 1449B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION LISTING OF REFERENCES May 15, 2009 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3211.1001-001		APPLICATION NO. 10/758,589	
	FIRST NAMED INVENTOR Keizo Koya		FILING DATE January 15, 2004	
	EXAMINER James D. Anderson	CONFIRMATION NO. 5403	GROUP 1614	

Examiner's Initials	Ref. No.	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	AX11	Vippagunta, <i>et al.</i> , "Crystalline solids," Advanced Drug Delivery Reviews, 48: 3-26, 2001.
	AY11	Vlemminckx, V., <i>et al.</i> , "Upregulation of HSP27 in a Transgenic Model of ALS," <i>J Neuropathol Exp Neurol</i> , 61(11): 968-974 (2002).
	AZ11	Voss, R.M., <i>et al.</i> , "Gender Differences in the Expression of Heat Shock Proteins: The Effect of Estrogen," <i>Am J Physiol Heart Circ Physiol</i> , 285: H687-H692 (2003).
	AR12	Wust, P. <i>et al.</i> , "Hyperthermia in Combined Treatment of Cancer," <i>The Lancet Oncology</i> , 3(8): 487-497 (August 2002), XP004813895.
	AS12	Yenari, M.A., "Heat Shock Proteins and Neuroprotection," <i>Adv Exp Med Biol</i> , 513: 281-299 (2002).
	AT12	Yu, Q., <i>et al.</i> , "Retinal Uptake of Intravitreally Injected Hsc/Hsp70 and its Effect on Susceptibility to Light Damage," <i>Molecular Vision</i> , 7: 48-56 (2001).
	AU12	Zhang, Y., <i>et al.</i> , "Estrogen and Androgen Protection of Human Neurons Against Intracellular Amyloid β_{1-42} Toxicity Through Heat Shock Protein 70," <i>J Neuroscience</i> , 24(23): 5315-5321 (2004).
	AV12	Rupp, Walter, "5-Amino-1,3,4-Thiadiazole Compounds," CA76:126992, 1972.
	AW12	Schwarz <i>et al.</i> , "Virustatic Thiosemicarbazides," CA77:48081, 1972.
	AX12	
	AY12	
	AZ12	

EXAMINER /James Anderson/	DATE CONSIDERED 09/16/2009
------------------------------	-------------------------------